Grab your favorite coffee. This is where you’ll find all the substance you require, and more.
The placebo response in drug development. Part 2: Osteoarthritis
Osteoarthritis (OA) is common musculoskeletal disease with increased incidence and prevalence associated with aging. It affects around 10 % of the population and is 10 times more…
Are clinical trials patients’ reactions to crisis related to their personality? Application to the COVID-19 pandemic.
Not only are patient visits to clinical sites more difficult (or impossible), patients are also dealing with uncertainty, stress and anxiety. While keeping ongoing trials running is…
Data Integrity in GCP environment
As clinical trials become more complex, are conducted at more sites with multiple vendors (clinical sites, CROs, e-PRO, data management vendors, etc.), properly protecting data integrity becomes…
The Placebo response in drug development. Part 1: Rheumatoid Arthritis
Evidence has accumulated in recent years that the placebo response is a significant issue in evaluating efficacy of drugs for rheumatoid arthritis (RA). RA is a chronic…
The Opioid Crisis in the US: Fueling the Next Wave of Drug Development for Chronic Pain
While the opioid crisis may be creating opportunity for development of novel therapies to treat chronic pain, drug development in this area has historically struggled. According to…
Tools4Patient: Starting a new year with 20/20 hindsight
As 2019 came to a close and we begin a new decade, it’s an excellent opportunity to evaluate and learn from the past year and set a…
Understand patient differences in your next clinical trial
Increase clinical trial success rates and get new therapies to patients faster. Tell us about your clinical trial below and we'll be in touch.
"*" indicates required fields